Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The National Ovarian Cancer Coalition Supports & Encourages Participation in Nationwide Ovarian Cancer Healthy Lifestyle Study through UA Cancer Center
  • USA - English


News provided by

National Ovarian Cancer Coalition, Inc.

Sep 05, 2013, 03:00 ET

Share this article

Share toX

Share this article

Share toX

www.ovarianlives.org
www.ovarianlives.org

Dallas, TX (PRWEB) September 05, 2013 -- The National Ovarian Cancer Coalition (NOCC) is partnering with the GOG (Gynecologic Oncology Group), National Cancer Institute (NCI) and others in funding the GOG 0225, LIvES Study*. This is the first large, nationwide trial seeking to determine how diet and physical activity together can improve the quality of life and prevent recurrence among women diagnosed with ovarian cancer. The trial is being overseen by the University of Arizona Cancer Center (UACC).

I have everything to gain from this study and hopefully it will benefit people down the line. I am so excited to be doing some good.

Post this

The NOCC is committed to furthering research efforts that focus on better detecting ovarian cancer and on improving quality of life for those affected by ovarian cancer. Overall, the ten-year survival rate for ovarian cancer is only 34% (ACS Cancer Facts & Figures, 2013). The main objective of this landmark study is to determine if the lifestyle intervention group experiences improved quality of life and survival in comparison to the usual care group.

Only around three percent of cancer patients participate in clinical trials nationally. "To make scientific progress will take a critical mass of patients and practices willing to participate in ovarian cancer clinical trials, along with the funding to support this research," says David Barley, Chief Executive Officer for the National Ovarian Cancer Coalition.

Few trials have been conducted in the areas of diet and physical activity, though growing evidence suggests both may play an integral role in ovarian cancer, which has a high recurrence rate. A participant at Maine Medical Center shares, "I have everything to gain from this study and hopefully it will benefit people down the line. I am so excited to be doing some good."

The LIvES (Lifestyle Intervention for Ovarian Cancer Enhanced Survival) study is recruiting 1,070 stage II-IV ovarian, primary peritoneal and fallopian tube cancer survivors from GOG clinics across the country. As of August 2013, 220 clinic sites and 155 participants are enrolled.
• The study will use an innovative combination of telephone and web-based coaching software designed specifically for GOG 0225.
• Each woman will be randomly assigned to either the intervention or usual care group. Both groups will receive telephone-based coaching from UACC.
• The study participants will be contacted by UACC a minimum of 22 times over the two-year period.
• Women will be asked to fill out questionnaires regarding their diet, physical activity, other lifestyle and health issues, and overall quality of life. Blood samples will also be collected.
"This trial fills a huge gap concerning what women can do to stay healthy and free of ovarian cancer after chemotherapy successfully has been completed," says David S. Alberts, MD, UACC director and co-chair of the LIvES study. At the UACC, Dr. Alberts helps to coordinate Phase I and II and pharmacokinetic drug studies for molecularly-targeted chemopreventive agents and anticancer drugs. His research, for more than 35 years, has involved innovative treatments for advanced ovarian cancers.

This year alone approximately 22,240 women in the U.S. will be diagnosed with ovarian cancer (ACS Cancer Statistics, 2013) and there are estimated to be over 180,000 women alive in the U.S. who have been diagnosed with ovarian cancer (NCI SEER Program, 2009). The NOCC is committed to this research endeavor and working with the researchers to further explore the role that lifestyle may have regarding ovarian cancer. Read more about participating in this trial at http://www.ovarianlives.org. Also visit NOCC’s clinical trials page at http://www.ovarian.org/clinical_trials.php.

*The LIvES Study is supported in part by grant number CA101165 from the National Cancer Center of the National Institutes of Health.

About the National Ovarian Cancer Coalition

Since its inception in 1995, the National Ovarian Cancer Coalition (NOCC) has been committed to raising awareness of ovarian cancer and providing support, education, and hope for women affected by ovarian cancer, and their families. Establishing itself as an important national advocate for ovarian cancer patients, the NOCC remains steadfast in its mission to raise awareness and promote education about ovarian cancer. The Coalition aims to improve the survival rate and quality of life for ovarian cancer patients and provide resources to family and friends of ovarian cancer survivors.

http://www.ovarian.org | 888-OVARIAN

Christina Lizaso, National Ovarian Cancer Coalition, Inc., (214) 273-4211, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.